Search
Black Diamond Therapeutics Inc
BDTXAdd to Watchlist
1.690USD
-0.025-1.46%
Close 07-31 16:00（ET）Quotes delayed by 15 min
96.84MMarket Cap
LossP/E TTM
More Details of Black Diamond Therapeutics Inc Company
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Black Diamond Therapeutics Inc Info
Ticker SymbolBDTX
Company nameBlack Diamond Therapeutics Inc
IPO dateJan 30, 2020
CEOVelleca (Mark A)
Number of employees24
Security typeOrdinary Share
Fiscal year-endJan 30
Address245 First Street, 18Th Floor
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16174175868
Websitehttps://www.blackdiamondtherapeutics.com/
Ticker SymbolBDTX
IPO dateJan 30, 2020
CEOVelleca (Mark A)
Company Executives of Black Diamond Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
102.53K
+8.74%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
45.04K
+17.56%
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.08K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Brent M. Hatzis-Schoch, Esq.
Mr. Brent M. Hatzis-Schoch, Esq.
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
102.53K
+8.74%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
45.04K
+17.56%
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.08K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
FAQs
Who are the top five shareholders of Black Diamond Therapeutics Inc?
The top five shareholders of Black Diamond Therapeutics Inc are: Dr. Ali Behbahani, M.D.
How many institutions hold shares of Black Diamond Therapeutics Inc (BDTX)?
As of 2026Q1, 265 institutions hold shares of Black Diamond Therapeutics Inc, with a combined market value of approximately 45.02M, accounting for 78.72% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -14972289.00.